
About Cytokinetics
Cytokinetics is a publicly listed company based in San Francisco (United States) founded in 1997. Muscle activators are developed for debilitating diseases. Cytokinetics has raised $60 million across 11 funding rounds from investors including Morgan Stanley, Duke University and HHS. The company has 498 employees. Its website cytokinetics.com draws about 25 thousand monthly visits. Cytokinetics offers products and services including Cardiac Myosin Inhibitors and Muscle Activators. Its focus areas include Life Sciences, Orthopedics, Drugs and Muscle Disorders. Its competitors include AskBio, BioAge Labs and Solid Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
Cytokinetics was founded in 1997 and is headquartered in San Francisco, United States. Operations focus on the biotechnology sector, where muscle activators are developed as treatments for conditions such as heart failure and spinal muscular atrophy. The drug pipeline includes omecamtiv mecarbil, a cardiac myosin activator investigated in collaboration with Amgen, and CK-2127107, a skeletal muscle troponin activator targeted at SMA patients.
- Headquarters San Francisco, United States
- Employees 498
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website cytokinetics.com
- Social LinkedIn X Facebook YouTube
- Legal Name Cytokinetics, Incorporated
- Annual Revenue$88.04 M (USD)376.56as on Dec 31, 2025
- Net Profit-$784.96 M (USD)-33.15as on Dec 31, 2025
- EBITDA-$602.13 M (USD)-14.32as on Dec 31, 2025
- Total Equity Funding$60M (USD)
in 11 rounds
- Latest Funding Round$450M (USD), Post-IPO
Jul 2022
- InvestorsMorgan Stanley
& 5 more
- Employee Count498
Products & Services of Cytokinetics
Cytokinetics offers a comprehensive portfolio of products and services, including Cardiac Myosin Inhibitors and Muscle Activators.
Inhibitors targeting heart failure and hypertrophic cardiomyopathy treatments
Activators for neuromuscular disease management and function improvement
Apps and channels of Cytokinetics
its YouTube channel Cytokinetics has 513 subscribers and 30 videos.
Videos from Cytokinetics
The most watched videos on Cytokinetics's YouTube channel, Cytokinetics (513 subscribers). Click a video to play it here.
More on Cytokinetics.
Funding Insights of Cytokinetics
Cytokinetics has successfully raised a total of $60M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $450 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $60M
- Total Rounds 11
- Last Round Post-IPO β $450M
- First Round $20M
(Oct 1999)
- Investors Count 6
Latest 10 of 11 funding rounds of Cytokinetics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2022 | $450M | Post-IPO | β | β | β |
| Jul 2020 | Post-IPO | β | β | β | |
| Nov 2019 | $138M | Post-IPO | β | β | β |
| May 2017 | $75M | Post-IPO | β | β | |
| Jun 2013 | $10M | Post-IPO | β | β | |
| Jul 2010 | $3.48M | Grant | β | β | |
| Jul 2010 | $3.48M | Grant | β | β | |
| Sep 2008 | $99,992 | Grant | β | β | |
| Sep 2008 | $99,992 | Grant | β | β | |
| Apr 2003 | $40M | Series C | β | β | β |
6 investors in total: 6 institutional.
Investors in Cytokinetics
Cytokinetics has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Morgan Stanley, Duke University and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are facilitated by Amgen-backed entity. | amgenbd.com | Thousand Oaks, United States | ||
| vulcanventuresinvestments.com | ||||
Early-stage US investments in technology and offline sectors are targeted. | srfunds.com | Dallas, United States | ||
Wealth management, investment advisory, and financial services are provided. | 1935 | morganstanley.com | New York, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Multiple courses and degrees across diversified streams are offered. | 1838 | duke.edu | United States |
Investor details for Cytokinetics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cytokinetics
299 people are tracked at Cytokinetics (165 in leadership, 20 in board & advisors, 114 in team); the tracked headcount is 498.
| Name | Role | Group |
|---|---|---|
Jonathan Kaltman | Senior Medical Director, Clinical Research Cardiovascular | Leadership |
Prodromos Anthopoulos | VP, Head of Medical Affairs, Europe | Leadership |
Robert Blum | President & CEO | Leadership |
Colleen Healy | Director, Professional Society Engagement | Leadership |
Amy Diehl | Director, Market Development Lead | Leadership |
Norma Tom | VP, Chemistry, Manufacturing and Control | Leadership |
Jeff Lotz | VP, Sales and Operations | Leadership |
Armina Fortuna Riethmuller | Director, Drug Safety Operations, Compliance Europe And Deputy EU QPPV | Leadership |
Daryl Luey | Director, Quality Assurance | Leadership |
Andrew Callos | EVP, Chief Commercial Officer | Leadership |
John Faurescu | Vice President, Head Of Legal & Corporate Secretary | Leadership |
Boris Velinov | Global Marketing Director | Leadership |
Amish Patel | Associate Director, Drug Safety Physician | Leadership |
Stuart Kupfer | SVP, Chief Medical Officer | Leadership |
Spencer Y. | Director, Regulatory Project Management | Leadership |
Rose Ann P. | Associate Director Human Resources | Leadership |
Amy Wang | Director, Tech Ops CMC Analytical | Leadership |
Bob Wegner | Director, Marketing Capabilities And Operations | Leadership |
Blanca B. | Associate Director Of Patient Support Services | Leadership |
Camelia Dumitrescu | Head Of Drug Safety And Pharmacovigilance | Leadership |
279 more people are available in the full profile.
Complete people profiles for Cytokinetics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Cytokinetics
Cytokinetics is a publicly listed company on the NASDAQ with ticker symbol CYTK in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date29 Apr 2004
- Listed onNASDAQ: CYTK
- Listed entityCytokinetics, Incorporated
- Exchange sectorHealth technology
- ISINUS23282W6057
- Share price$61.62 (-1.86% on the day) · 2026-10-13
- Market capitalisation$8.57B
- EPS (diluted, trailing year)$-7.22
- Volume (last session)1,935,973
Financials of Cytokinetics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $88.0M | -$785.0M | -$602.1M |
| 2024 | $18.5M | -$589.5M | -$526.7M |
| 2023 | $7.5M | -$526.2M | -$484.3M |
| 2022 | $94.6M | -$388.9M | -$315.8M |
| 2021 | $70.4M | -$215.3M | -$176.7M |
Detailed financial statements for Cytokinetics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Cytokinetics
4 dated milestones of Cytokinetics across 25 years, from founding to its latest funding, stage changes and deals.
- Founded Cytokinetics is founded.
- Funding First funding round of $20.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $450.0M.
Competitors of Cytokinetics
Cytokinetics has 3 listed competitors in our database, 3 of them funded. They include AskBio, BioAge Labs and Solid Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| askbio.com | 2001 | Durham, United States | $235M | Gene and protein therapies are developed for treating various diseases. | ||
| bioagelabs.com | 2015 | Vallejo, United States | $293.9M | 43 | Bioinformatics platform is provided for biomarkers and drug discovery. | |
| solidbio.com | 2014 | Cambridge, United States | $92.5M | 101 | Gene therapy platform for Duchenne muscular dystrophy is developed. |
Detailed competitors of Cytokinetics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cytokinetics
The website of Cytokinetics (cytokinetics.com) receives about 25.3K visits a month and ranks #1,072,700 among all websites worldwide, #1,325 in Biotechnology and Pharmaceuticals.
- Monthly visits25.3K
▲ 5.8% vs previous month
- Unique visitors13.4K
per month
- Global rank#1,072,700
among all websites
- Category rank#1,325
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit2.3
- Average visit56 sec
- DevicesDesktop 62% Β· Mobile 38%
Websites whose visitors overlap most with Cytokinetics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| denalitherapeutics.com | 100% | 26.9K | #914,827 | View details | |
| cytori.com | 100% | 1.3K | #12,091,883 | View details | |
| mazetx.com | 99% | 9.2K | #2,405,150 | View details | |
| ctibiopharma.com | 94% | View details | |||
| lenz-tx.com | 93% | 20.1K | #1,219,956 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 11 similar websites and full traffic analytics for Cytokinetics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Orthopedics
3 companies that operate in the same segment as Cytokinetics (Orthopedics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of high-frequency spinal cord stimulation implants | 2006 | Menlo Park, California, United States | USD 154.1 M | USD 353.08 M | 1,215 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Antibody-siRNA complexes are developed for cancer treatment. | 2012 | San Diego, California, United States | USD 142.54 M | USD 10.9 M | 391 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cytokinetics
Complete news archive for Cytokinetics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cytokinetics
Cytokinetics was founded in 1997 and raised its 1st funding round 2 years after it was founded.
Cytokinetics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Cytokinetics is a funded company, having raised a total of $60M across 11 funding rounds to date. The company's 1st funding round was a Series C of $40M, raised on Oct 1999.
Cytokinetics has 498 employees.
Annual revenue of Cytokinetics is $88.04M as on Dec 31, 2025.
Cytokinetics was founded in 1997 and is headquartered in San Francisco, United States. Operations focus on the biotechnology sector, where muscle activators are developed as treatments for conditions such as heart failure and spinal muscular atrophy. The drug pipeline includes omecamtiv mecarbil, a cardiac myosin activator investigated in collaboration with Amgen, and CK-2127107, a skeletal muscle troponin activator targeted at SMA patients.
Cytokinetics's top competitors include AskBio, Solid Biosciences and BioAge Labs.
Cytokinetics offers Cardiac Myosin Inhibitors and Muscle Activators.
Yes, Cytokinetics is publicly traded on NASDAQ under the ticker symbol CYTK.
Cytokinetics has 6 investors. Key investors include Morgan Stanley, Duke University, HHS, Amgen Business Development, and Vulcanventuresinvestments.com.
